Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake

Molecular Pharmacology(2022)10.1124/molpharm.121.000287Source: DataRank Database

Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake is a research paper published in Molecular Pharmacology (2022). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.02)OA: bronzeTopics (37)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Kenneth C. Anderson ORCID,Elizabeth R. Hayden ORCID,Kyle Z. Pasquariello ORCID,Alice A. Gibson ORCID,Shichen Shen

Live enrichment

PubMed:35383108 OpenAlex:https://openalex.org/W4226049749

National Institutes of Health

Grant: 5KL2TR001413-03

Buffalo Clinical and Translational Research Center

NCATS NIH HHS

Grant: KL2 TR001413

NIGMS NIH HHS

Grant: R01 GM139936

NCATS NIH HHS

Grant: UL1 TR001412

FWCI

1.02

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: Elsevier TDM

journalhttps://molpharm.aspetjournals.org/content/molpharm/101/6/381.full.pdf

publisherhttps://molpharm.aspetjournals.org/content/molpharm/101/6/381.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0026895X24011696?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0026895X24011696?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/molpharm.121.000287

Fields of Study

Drug Transport and Resistance MechanismsHIV/AIDS drug development and treatmentChronic Myeloid Leukemia TreatmentsDrug InteractionsLiver-Specific Organic Anion Transporter 1Membrane Transport ProteinsOrganic Anion TransportersOrganic Anion Transporters, Sodium-IndependentProtein Kinase InhibitorsProtein-Tyrosine KinasesSolute Carrier Organic Anion Transporter Family Member 1B3

MeSH Terms

Solute Carrier Organic Anion Transporter Family Member 1B3Drug InteractionsProtein-Tyrosine KinasesMembrane Transport ProteinsOrganic Anion TransportersLiver-Specific Organic Anion Transporter 1Organic Anion Transporters, Sodium-IndependentProtein Kinase Inhibitors

Keywords

Tyrosine kinaseTyrosine-kinase inhibitorNilotinibChemistryTyrosineBiochemistryPharmacologyBiologySignal transductionGeneticsSolute Carrier Organic Anion Transporter Family Member 1B3Liver-Specific Organic Anion Transporter 1Membrane Transport ProteinsOrganic Anion TransportersDrug InteractionsOrganic Anion Transporters, Sodium-IndependentProtein-Tyrosine KinasesProtein Kinase Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being